• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    12 Health Care Stocks Moving In Monday's Pre-Market Session

    10/16/23 9:05:49 AM ET
    $ALDX
    $AMAM
    $BIOC
    $BPTH
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ALDX alert in real time by email

    Gainers

    • Better Therapeutics (NASDAQ:BTTX) stock rose 56.7% to $0.49 during Monday's pre-market session. The market value of their outstanding shares is at $19.9 million.
    • Redhill Biopharma (NASDAQ:RDHL) stock increased by 31.21% to $0.42. The company's market cap stands at $2.4 million.
    • Processa Pharma (NASDAQ:PCSA) shares moved upwards by 28.47% to $0.62. The company's market cap stands at $15.1 million.
    • TransCode Therapeutics (NASDAQ:RNAZ) stock rose 22.74% to $0.53. The company's market cap stands at $1.9 million.
    • ContraFect (NASDAQ:CFRX) stock moved upwards by 22.67% to $0.7. The market value of their outstanding shares is at $3.8 million.
    • Ambrx Biopharma (NASDAQ:AMAM) stock rose 21.35% to $17.05.

    Losers

    • Aldeyra Therapeutics (NASDAQ:ALDX) shares fell 73.5% to $1.44 during Monday's pre-market session. The company's market cap stands at $84.3 million.
    • Biocept (NASDAQ:BIOC) shares decreased by 55.89% to $0.45. The market value of their outstanding shares is at $1.1 million.
    • Omeros (NASDAQ:OMER) stock declined by 45.82% to $1.23. The market value of their outstanding shares is at $77.3 million.
    • Leap Therapeutics (NASDAQ:LPTX) shares decreased by 19.08% to $1.23. The company's market cap stands at $31.4 million.
    • Bio-Path Hldgs (NASDAQ:BPTH) shares decreased by 17.2% to $0.62. The company's market cap stands at $7.1 million.
    • Streamline Health Solns (NASDAQ:STRM) shares declined by 16.11% to $0.62. The market value of their outstanding shares is at $36.5 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

    This article was generated by Benzinga's automated content engine and reviewed by an editor.

    Get the next $ALDX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ALDX
    $AMAM
    $BIOC
    $BPTH

    CompanyDatePrice TargetRatingAnalyst
    Omeros Corporation
    $OMER
    6/10/2025$9.00Buy
    H.C. Wainwright
    Leap Therapeutics Inc.
    $LPTX
    1/29/2025Buy → Neutral
    H.C. Wainwright
    Leap Therapeutics Inc.
    $LPTX
    1/29/2025$9.00 → $1.25Outperform → Neutral
    Robert W. Baird
    Omeros Corporation
    $OMER
    12/23/2024$36.00Buy
    D. Boral Capital
    Omeros Corporation
    $OMER
    11/14/2024$9.00Buy
    Rodman & Renshaw
    Leap Therapeutics Inc.
    $LPTX
    6/28/2024$8.00Buy
    Rodman & Renshaw
    Processa Pharmaceuticals Inc.
    $PCSA
    4/25/2024$8.00Buy
    H.C. Wainwright
    Aldeyra Therapeutics Inc.
    $ALDX
    4/3/2024$10.00Perform → Outperform
    Oppenheimer
    More analyst ratings

    $ALDX
    $AMAM
    $BIOC
    $BPTH
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    H.C. Wainwright initiated coverage on Omeros with a new price target

    H.C. Wainwright initiated coverage of Omeros with a rating of Buy and set a new price target of $9.00

    6/10/25 8:09:22 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics downgraded by H.C. Wainwright

    H.C. Wainwright downgraded Leap Therapeutics from Buy to Neutral

    1/29/25 7:15:39 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics downgraded by Robert W. Baird with a new price target

    Robert W. Baird downgraded Leap Therapeutics from Outperform to Neutral and set a new price target of $1.25 from $9.00 previously

    1/29/25 7:15:19 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $BPTH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of Cancer Patients

    TransCode adds a unique adenovirus technology platform to its early-stage pipeline that has the potential to address a difficult to treat disease such as muscle-invasive bladder cancer.BOSTON, March 3, 2026 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, today announced that it has entered into an exclusive, worldwide, fully paid-up royalty-free license agreement with Unleash Immuno Oncolytics, Inc. ("Unleash"). TransCode obtained the rights to develop three Unleash drug candidates, UIO-524, UIO-525 and UIO-526, which includes a license of all in-licensed rights held by

    3/3/26 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Biliary Tract Cancer Market is Predicted to Exhibit Remarkable Growth at a CAGR of 10.1% During the Forecast Period (2025-2034) | DelveInsight

    LAS VEGAS, March 2, 2026 /PRNewswire/ -- The biliary tract cancer market is experiencing steady growth driven by rising global incidence and improved diagnostic capabilities. Increasing adoption of targeted therapies and immuno-oncology approaches is expanding treatment options. Additionally, the launch of emerging drugs such as Tinengotinib (TransThera Sciences), Rilvegostomig (AstraZeneca), Nanvuranlat (JPH203) (J-Pharma/OHARA Pharmaceutical), Tovecimig (CTX-009) (Compass Therapeutics), Lenvatinib mesylate (LENVIMA) (Merck/Eisai), and others will further boost the market growth. Recently published Biliary Tract Cancer Market Insights report includes a comprehensive understanding of current

    3/2/26 5:31:00 PM ET
    $BOLD
    $CMPX
    $INCY
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Biotechnology: Biological Products (No Diagnostic Substances)
    Biotechnology: Commercial Physical & Biological Resarch

    Joint U.S. Commercialization of RedHill's Talicia® Commences

    The full sales and operational launch of Talicia, under the joint commercialization agreement between Talicia Holdings Inc. (THI), a jointly controlled entity of RedHill and Cumberland has started and is now being rolled out to support accelerated market penetration and expanded reachFocused on unlocking the full market potential of Talicia, the #1 branded U.S. gastroenterologist-prescribed H. pylori therapy1, THI and Cumberland will manage the launch and ongoing joint commercialization activitiesH. pylori infection affects 35% of the U.S. adult population and an estimated 1.6 million U.S. patients are treated annually2. Talicia is the only FDA-approved all-in-one, low-dose rifabutin-based H

    2/25/26 7:00:00 AM ET
    $CPIX
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $BPTH
    SEC Filings

    View All

    SEC Form DEFA14A filed by TransCode Therapeutics Inc.

    DEFA14A - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:06:34 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Other Events, Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Transcode Therapeutics, Inc. (0001829635) (Filer)

    3/3/26 4:05:39 PM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form S-8 filed by Aldeyra Therapeutics Inc.

    S-8 - Aldeyra Therapeutics, Inc. (0001341235) (Filer)

    2/27/26 5:07:16 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $BPTH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chairman, CEO & President Demopulos Gregory A Md exercised 400,000 shares at a strike of $10.27 and covered exercise/tax liability with 357,678 shares, increasing direct ownership by 3% to 1,469,308 units (SEC Form 4)

    4 - OMEROS CORP (0001285819) (Issuer)

    2/20/26 9:40:28 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Pres. Research & Development Young David converted options into 49 shares, increasing direct ownership by 0.56% to 8,752 units (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    2/4/26 5:09:36 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business - Strategy Off Lin Patrick converted options into 193 shares, increasing direct ownership by 12% to 1,753 units (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    2/4/26 5:07:34 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $BPTH
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Principal Financial Officer Alfieri Michael bought $13,250 worth of shares (2,500 units at $5.30) (SEC Form 4)

    4 - Aldeyra Therapeutics, Inc. (0001341235) (Issuer)

    8/15/25 4:09:59 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Yorke Justin W bought $9,889 worth of shares (12,400 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/31/25 5:06:27 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Ng George K bought $69,542 worth of shares (87,200 units at $0.80) (SEC Form 4)

    4 - Processa Pharmaceuticals, Inc. (0001533743) (Issuer)

    1/29/25 5:05:00 PM ET
    $PCSA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $BPTH
    Leadership Updates

    Live Leadership Updates

    View All

    TransCode Therapeutics Expands Leadership with Appointment of Jack E. Stover to Board of Directors

    BOSTON, Dec. 22, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), a clinical stage company pioneering immuno-oncology and RNA for the treatment of high risk and advanced cancer, announced the appointment of Jack E. Stover to its Board of Directors. Mr, Stover will join the Audit and the Nominating Committees as Dr. Magda Marquet steps down from the Audit Committee.  Mr. Stover brings more than three decades of executive leadership experience across public and private life sciences companies, spanning drug development, diagnostics, specialty pharmaceuticals, and capital formation.

    12/22/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

    Accomplished drug development leader to advance TransCode's mission of defeating cancer through RNA innovation and translational excellence BOSTON, Nov. 17, 2025 /PRNewswire/ -- TransCode Therapeutics, Inc. (NASDAQ:RNAZ), an immuno-oncology and targeted cancer therapy company with a focus on treating advanced malignancy, announced today the appointment of Dr. Michel Janicot, Ph.D., as consultant Senior Development Officer. Dr. Janicot brings more than 35 years of experience in pharmaceutical research, preclinical, and early clinical drug development across oncology and other therapeutic areas. He will serve initially on a part-time basis. 

    11/17/25 8:01:00 AM ET
    $RNAZ
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Leap Therapeutics Rebrands as Cypherpunk; Expands Leadership Team to Drive New Zcash Treasury Strategy

    Khing Oei appointed Chairman of the Board; Will McEvoy appointed Chief Investment Officer and Member of the Board; Cypherpunk Technologies Inc. announces acquisition of 203,775.27 ZEC. CAMBRIDGE, Mass., Nov. 12, 2025 /PRNewswire/ -- Leap Therapeutics, Inc. (NASDAQ:LPTX) today announced it will change its name to Cypherpunk Technologies Inc., and unveiled a digital asset treasury strategy to accumulate Zcash's native coin, ZEC. Cypherpunk has to date used $50 million of proceeds from the previously announced private placement to purchase 203,775.27 ZEC at an average purchase price of $245.37 per ZEC. In addition, the company also plans to change its ticker symbol to (NASDAQ:CYPH) as part of t

    11/12/25 7:00:00 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $BPTH
    Financials

    Live finance-specific insights

    View All

    Omeros Announces New Date for YARTEMLEA® Approval Conference Call

    — Omeros to Host Conference Call Wednesday, January 7, 2026 at 4:30 p.m. ET — Omeros Corporation (NASDAQ:OMER) today announced a revised date for its conference call to discuss the recent FDA approval of YARTEMLEA® (narsoplimab-wuug), the first and only therapy indicated for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA). To ensure broad participation following this significant milestone — and to accommodate shareholders' and investors' holiday schedules — the call will now take place on Wednesday, January 7, 2026 at 4:30 p.m. Eastern Time. Details for the webcast and registration remain unchanged and are provided below. We are excited to kick off th

    12/26/25 6:36:00 PM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Omeros' YARTEMLEA® – First and Only Therapy Indicated for TA-TMA

    – Omeros to Host Conference Call Monday, December 29, 2025 at 4:30 p.m. ET –  First and only approved option: YARTEMLEA® is the only approved treatment for hematopoietic stem cell transplant-associated thrombotic microangiopathy (TA-TMA) and is indicated for adults and children ages two years and older. High complete response (CR) rates: YARTEMLEA-treated patients achieved CR rates of 61% in the pivotal trial and 68% in the Expanded Access Program (EAP) among those with evaluable patient-level response data; CR defined as improvement in key laboratory values plus either improved organ function or transfusion independence. Strong survival benefit: 100-day survival from TA-TMA diagno

    12/24/25 9:00:00 AM ET
    $OMER
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Aldeyra Therapeutics Announces PDUFA Extension of the New Drug Application of Reproxalap for the Treatment of Dry Eye Disease

    Aldeyra Therapeutics, Inc. (NASDAQ:ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated diseases, today announced that the U.S. Food and Drug Administration (FDA) has extended the Prescription Drug User Fee Act (PDUFA) target action date for the reproxalap New Drug Application (NDA) for the treatment of dry eye disease. The extended PDUFA target action date is March 16, 2026. Following submission on June 16, 2025, the NDA was accepted for review as a "complete class 2 response" by the FDA on July 16, 2025, with a target PDUFA action date of December 16, 2025. On December 12, 2025, the FDA met with Aldeyra to r

    12/15/25 7:30:00 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ALDX
    $AMAM
    $BIOC
    $BPTH
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Aldeyra Therapeutics Inc.

    SC 13G/A - Aldeyra Therapeutics, Inc. (0001341235) (Subject)

    11/14/24 4:50:29 PM ET
    $ALDX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Redhill Biopharma Ltd.

    SC 13G/A - RedHill Biopharma Ltd. (0001553846) (Subject)

    11/14/24 12:22:08 PM ET
    $RDHL
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Leap Therapeutics Inc.

    SC 13G - LEAP THERAPEUTICS, INC. (0001509745) (Subject)

    11/14/24 6:07:56 AM ET
    $LPTX
    Biotechnology: Pharmaceutical Preparations
    Health Care